ClinicalTrials.gg
TerminatedNCT03844932Updated May 7, 2021

A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis

A Phase 2 interventional study of ST-0529 in Colitis, Ulcerative, sponsored by Sublimity Therapeutics Holdco Limited. Terminated at 89 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-07.

Sponsored by Sublimity Therapeutics Holdco Limited · Phase 2, Interventional, and Treatment

Why this study was terminated
The Sublimity Board of Directors carefully evaluated the IA data: the 9.6% treatment remission difference for 75mg BID vs placebo (due to an increase in placebo response rate) was determined not sufficient to continue to fund the study

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
235
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies in Colitis, Ulcerative with a site in Ukraine — 11 open to participants now, 19 under way, 9 of them phase 3. Colitis, Ulcerative · Ukraine.

Enrollment
64th of 114
235 · median 267
Started
2019
with 13 others
Phase 2
48 of 115
6 open now
Registered
68th of 115
by date

Among the 115 studies in Colitis, Ulcerative with a site in Ukraine, this one is the 64th largest by enrollment of the 114 interventional ones that give a count, is one of 14 that started in 2019, is one of 48 in phase 2, and was the 68th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

11 of the 115 studies in Colitis, Ulcerative with a site in Ukraine are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Colitis, Ulcerative with a site in Ukraine, or all of them as a file.
02

Study summary

Study CYC-202 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ST-0529 in subjects with moderately to severely active UC, defined as a score of 5 to 9 on the 3-Component Adapted Mayo Score (comprised of rectal bleeding, stool frequency and endoscopy sub-scores; score range 0-9).

Read the detailed description

The study consists of a Screening period, Treatment period and Follow-up. The Screening period is comprised of two separate in-clinic visits, SV1 and SV2. At the initial Screening visit (SV1), subjects will be required to provide written informed consent to participate in the study and will then be assessed for eligibility. Electronic diaries will be provided to subjects at this visit to use for the duration of the study in order to record information relating to their UC disease. Subjects will return to the clinic for their Screening endoscopic assessment (SV2). Ulcerative colitis disease activity for eligibility will be assessed using the 3-Component Adapted Mayo Score. Upon successful completion of the Screening period, subjects will return to the clinic for their Baseline visit.

During the Treatment period, subjects will be evaluated in the clinic at Baseline (Day 1), Week 2, Week 4, Week 8, and Week 12 (End of Treatment Period). At Week 6 and Week 10, subjects will be contacted by telephone to assess Adverse Events (AEs), concomitant medication usage and study drug regimen adherence.

Subjects who complete the 12-week Treatment period will attend the Week 16 End of Study (EOS) visit. Subjects who discontinue study drug and withdraw or are withdrawn from the study before the Week 12 visit will be requested to return to the clinic as soon as possible to complete an Early Termination (ET) visit.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female adult subjects 18 to 75 years old, inclusive.
  2. Willing to provide written and to be compliant with the schedule of study visits and protocol assessments.
  3. Diagnosis of UC established at least 3 months prior to the Baseline visit, by clinical and endoscopic evidence (colonoscopy or flexible sigmoidoscopy)
  4. Moderately to severely active UC defined as the 3-Component Adapted Mayo Score of 5-9, inclusive, with an endoscopic sub-score of ≥ 2 (from central reading), and a rectal bleeding sub-score of ≥ 1, as determined 10 days (± 3 days) prior to Baseline.
  5. Evidence of active UC, confirmed histologically (from local read), extending proximal to the rectum with ≥ 15 cm of involved colon.
  6. At Screening, a colonoscopy will be required if the subject has had extensive colitis or pancolitis of > 8 years duration or left-sided colitis of > 12 years duration but has not had a colonoscopy within 1 year of the initial screening date. If the subject has had a colonoscopy within 1 year of the initial screening date, a flexible sigmoidoscopy may be used.
  7. Subjects presenting at Screening with moderately to severely active UC demonstrating an inadequate response or loss of response or intolerance/medical to at least one of the following conventional therapies for UC:

    a. :

    i. Signs and symptoms of active disease despite treatment with an adequate dose (e.g., prednisolone > 40 mg/day or equivalent) over a period of 4 weeks for oral therapy or intravenously (IV) for up to 1 week or ≥ 9 mg/day oral budesonide;

    OR

    ii. Unable to reduce corticosteroids below the equivalent of prednisolone 10 mg daily orally within 3 months of starting steroids or having experienced a relapse within 3 months of stopping steroids;

    OR

    iii. History of, or current intolerance to corticosteroids (including, but not limited to Cushing's syndrome, osteopenia/osteoporosis, hyperglycemia, insomnia, infection).

    b. Immunomodulators:

    i. Signs and symptoms of active disease despite at least 3 months of treatment with a sufficient dose (oral azathioprine ≥ 1.5 mg/kg or 6-mercaptopurine [6-MP] ≥ 0.75 mg/kg);

    OR

    ii. History of, or current dose-limiting toxicity associated with use of the agent (e.g., but not limited to nausea/vomiting, abdominal pain, pancreatitis, liver function test [LFT] abnormalities, lymphopenia, TPMT genetic mutation, infection).

    c. Anti-tumor necrosis factor (anti-TNF) agents:

    i. Signs and symptoms of active disease despite treatment with a single anti-TNF agent. Treatment failure is defined as a relapse after an initial response to therapy as follows:

    • Infliximab: At least 4 infusions of at least 5 mg/kg within a 14-week timeframe for induction and maintenance;
    • Adalimumab: Induction regimen incorporating 160 mg at Week 0 (four 40 mg injections in one day or two 40 mg injections per day for two consecutive days) and 80 mg at Week 2, followed by maintenance treatment of 40 mg every other week up to at least Week 8;
    • Golimumab: Induction regimen incorporating 200 mg subcutaneous (sc) injection at Week 0, followed by 100 mg at Week 2 and then maintenance treatment of 50 mg or 100 mg (weight dependent) every 4 weeks after completion of the induction regimen up to at least Week 12;

    OR

    ii. History of, or current intolerance (with an initial response), defined as the presence of side-effects, including infusion-related .

    d. Vedolizumab:

    i. Signs and symptoms of active disease despite a history of at least one induction regimen, defined as at least a 14-week (10 weeks in the EU) induction consisting of 300 mg IV at Weeks 0, 2 and 6.

    OR

    ii. History of intolerance to vedolizumab including, but not limited to, serious infections, hepatotoxicity, heart failure, allergic reactions, or any other condition that contributed to discontinuation of the agent.

  8. Subjects receiving oral corticosteroids for the treatment of UC must be on a stable dose of ≤ 40 mg/day (prednisolone or equivalent), or ≤ 9 mg/day budesonide. This dose must be stable from the initial Screening visit until 1 week after the initiation of study treatment.
  9. Subjects receiving oral 5-ASA must be on a stable dose from the initial Screening visit until the end of the study.
  10. Subjects willing to cease the use of any therapeutic enema or suppository or foams, other than that required in preparation for study-mandated colonoscopy/flexible sigmoidoscopies, from the initial Screening visit until the end of the study.
  11. Subjects willing to cease use of azathioprine or 6-MP from the initial Screening visit until the end of the study.
  12. Negative serum pregnancy test in females of at Screening.
  13. If female and of childbearing potential, must agree to be sexually abstinent or use one of the following highly effective methods of from the initial Screening visit until 30 days after the last dose of study drug is administered:

    1. Hormonal contraceptives (e.g., combined oral contraceptives, patch, vaginal ring, injectables, and implants);
    2. Intrauterine contraceptive system;
    3. Surgical sterilization or partner sterile (must have documented proof);

    AND

    One of the following effective methods of birth control:

    1. Male/female condom;
    2. Cervical cap with spermicide;
    3. Diaphragm with spermicide;
    4. Contraceptive sponge.
  14. Male subjects must be either surgically sterile (must have documented proof), agree to be sexually inactive or use a double-barrier method of birth control (e.g., condom and diaphragm with spermicide, condom with cervical cap and spermicide) from first study drug administration until 90 days after final drug administration.

Exclusion criteria

Exclusion Criteria:

If a subject has any of the following criteria, they will be excluded from the study:

  1. Subjects without previous treatment for UC.
  2. Ulcerative colitis limited to rectum (ulcerative proctitis).
  3. Evidence of acute severe colitis with toxic megacolon, abdominal abscess, bowel stricture or bowel perforation.
  4. A diagnosis of Crohn's colitis, colitis yet to be classified, ischemic colitis, NSAID-induced colitis, idiopathic colitis (i.e., colitis not consistent with UC) or radiation colitis.
  5. Subjects with evidence of pathogenic bowel infection (Clostridium difficile, Escherichia coli, Salmonella, Shigella or Campylobacter).
  6. Previous surgery for UC or, in the opinion of the Investigator, will likely require surgery for UC during the study.
  7. Any histological evidence of mucosal dysplasia.
  8. Subjects with a current or recent history of severe, progressive or uncontrolled cardiac (including uncontrolled hypertension), renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurological (e.g., history of seizures) disease, abnormal magnesium or potassium levels, hypocholesterolemia, or any other severe co-morbidity that, in the opinion of the Investigator, could confound the study results or put the study subject at unreasonable risk.
  9. or history of malignancy within 5 years of the initial Screening visit, with the exception of adequately treated or excised non- basal cell carcinoma or squamous cell carcinoma of the skin.
  10. Any of the following laboratory abnormalities during the screening period - if values are initially outside the prescribed limits, the evaluation may be repeated once within the screening period to determine eligibility:

    1. level \< 8.0 g/dL
    2. Absolute WBC count \< 3.0 × 10\^9/L
    3. Absolute Lymphocyte count \< 0.5 × 10\^9/L
    4. \< 1.2 × 10\^9/L
    5. count \< 100 × 10\^9/L or >1200 × 10\^9/L
    6. or AST > 2.0 ×
    7. Alkaline phosphatase > 2.0 × ULN
    8. Serum creatinine > 1.5 × ULN
    9. > 1.5 × ULN
  11. Subjects with active TB infection or known history of prior treated or untreated TB infection.
  12. Subject with a positive serology test result for (HIV type 1 or type 2).
  13. Subject with a positive serology test result for active or infection.
  14. Treatment with biologic agents for UC within 56 days or 5 half-lives (whichever is greater) prior to the Baseline visit.
  15. Treatment with any calcineurin inhibitor (e.g. cyclosporine or tacrolimus) within 28 days prior to the Baseline visit.
  16. Treatment with methotrexate or JAK inhibitors (e.g. tofacitinib) from the initial Screening visit until the end of the study.
  17. Initiation of treatment with an oral or IV from the initial Screening visit until the end of the study.
  18. Use of any strong inhibitors of CYP enzymes (e.g., cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem, grapefruit juice and HIV antivirals) within 14 days prior to the Baseline visit.
  19. Use of strong or moderate P-gp inhibitors (e.g., amiodarone, azithromycin, clarithromycin, itraconazole, ketoconazole, dronedarone, lapatinib, quinidine, ranolazine, verapamil) within 14 days prior to the Baseline visit.
  20. Use of any herbal medication for the treatment of UC or which might interfere with CYP enzymes within 14 days prior to the Baseline visit.
  21. Subjects vaccinated with a live or within 14 days of the Baseline visit, or planned vaccination during conduct of the study.
  22. Subjects with a of > 450 ms for males and > 470 ms for females at Screening.
  23. A history of risk factors for Torsades de pointes (e.g., history of heart failure, hypokalemia, family history of Long QT Syndrome).
  24. Known to cyclosporine or any contained in ST-0529.
  25. History of alcohol or drug abuse in the year prior to the initial Screening visit.
  26. Subjects currently breast feeding, pregnant, or unwilling to delay initiation of breast feeding for at least 90 days after the last dose of study drug is administered.
  27. Participation in another clinical trial and having received medication within 30 days or within 5 half-lives (whichever is longer) prior to the Baseline visit, or concurrent participation in another clinical trial.
  28. Subjects who, in the opinion of the Investigator, are unsuitable for inclusion in the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
235 participants (actual)

Study arms

  • Experimental
    ST-0529 18.75 mg*

    ST-0529: 18.75 mg orally twice daily (BID) \*Jan 2021 update: following the IDMC recommendation, this arm has been dropped

    Drug: ST-0529

  • Experimental
    ST-0529 37.5 mg*

    ST-0529: 37.5 mg orally twice daily (BID) \*Jan 2021 update: following the IDMC recommendation, this arm has been dropped

    Drug: ST-0529

  • Experimental
    ST-0529 75 mg

    ST-0529: 75 mg orally twice daily (BID)

    Drug: ST-0529

  • Placebo comparator
    Matching Placebo

    Placebo: matching placebo orally twice daily (BID)

    Drug: ST-0529

Interventions

  • ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.

    Also known as: cyclosporine

06

What researchers measure

Primary outcomes

  1. Clinical Remission at Week 12

    Stool frequency sub-score of ≤ 1 associated with a decrease ≥ 1 point from baseline, rectal bleeding sub-score of 0, and an endoscopic sub-score of ≤ 1 using the 3-Component Adapted Mayo Score. The 3-Component Adapted Mayo Score is a measure of UC disease ranging from 0 to 9 points and consists of 3 sub-scores, each graded from 0 - 3 with higher scores indicating more severe disease. The sub-scores are stool frequency (0 - 3); rectal bleeding (0 - 3); findings of endoscopy (0 - 3).

    Time frame: Week 12

Secondary outcomes

  1. Clinical Response at Week 12

    A decrease from baseline in the 3-Component Adapted Mayo Score of ≥ 2 points and ≥ 30%, with an accompanying decrease in the sub-score for rectal bleeding of ≥ 1 point or an absolute sub-score for rectal bleeding of ≤ 1. The 3-Component Adapted Mayo Score is a measure of UC disease ranging from 0 to 9 points and consists of 3 sub-scores, each graded from 0 - 3 with higher scores indicating more severe disease. The sub-scores are stool frequency (0 - 3); rectal bleeding (0 - 3); findings of endoscopy (0 - 3).

    Time frame: Week 12

  2. Endoscopic Healing at Week 12

    Endoscopic Healing (I) defined as an endoscopic sub-score of ≤ 1. The endoscopic sub-score is part of the 3-Component Adapted Mayo score and ranges from 0 - 3, with higher scores indicating more severe disease.

    Time frame: Week 12

  3. Corticosteroid-free clinical response at Week 12

    Clinical response and achieving a corticosteroid-free status at Week 12 in subjects using oral corticosteroids at the Baseline visit. Clinical response is defined as a decrease from baseline in the 3-Component Adapted Mayo Score of ≥ 2 points and \> 30%, with an accompanying decrease in the sub-score for rectal bleeding of ≥ 1 point or an absolute sub-score for rectal bleeding of ≤ 1.

    Time frame: Week 12

  4. Corticosteroid-free clinical remission at Week 12

    Clinical remission and achieving a corticosteroid-free status at Week 12 in subjects using oral corticosteroids at the Baseline visit. Clinical remission is defined as a stool frequency sub-score of ≤ 1 associated with a decrease ≥ 1 point from baseline, rectal bleeding sub-score of 0, and an endoscopic sub-score of ≤ 1 using the 3-Component Adapted Mayo Score.

    Time frame: Week 12

  5. Changes from baseline in individual Adapted Mayo sub-scores at Week 12

    The Adapted Mayo Score is a measure of UC disease ranging from 0 to 12 points and consists of 4 sub-scores, each graded from 0 - 3 with higher scores indicating more severe disease. The sub-scores are stool frequency (0 - 3); rectal bleeding (0 - 3); findings of endoscopy (0 - 3); and Physician's Global Assessment \[PGA\] (0 - 3).

    Time frame: Week 12

07

Study locations

89 sites
  • Palmtree Clinical Research Inc
    Palm Springs, California 92262, United States
  • Advanced Research Institute
    Largo, Florida 33377, United States
  • Advanced Research Institute, Inc.
    New Port Richey, Florida 34653, United States
  • Endoscopic Research Inc
    Orlando, Florida 32803, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • AGA Clinical Reasearch Associates, LLC
    Egg Harbor Township, New Jersey 08234, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Biopharma Informatic, LLC.
    Houston, Texas 77084, United States
  • Gomel Regional Clinical Hospital
    Gomel, 246 029, Belarus
  • Grodno Regional Clinical Hospital
    Grodno, 230017, Belarus
  • City Clinical Emergency Hospital
    Minsk, 220024, Belarus
  • MedConsult Pleven
    Pleven, 5800, Bulgaria
  • Medical Center Asklepion
    Sofia, 1303, Bulgaria
  • UMBAL Tsaritsa Joanna ISUL
    Sofia, 1527, Bulgaria
  • Dalhousie University - Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia B3H 2Y9, Canada
  • London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • CHU Amiens Picardie - Service Hépato-Gastroentérologie
    Amiens, 80054, France
  • CHU DE MONTPELLIER - Hôpital St ELOI
    Montpellier, 34295, France
  • CHU de Saint-Etienne - Service de Gastro-Entérologie-Hépatologie
    Saint-Étienne, 42055, France
  • Hôpital de Brabois Service d'Hépato-Gastro-Entérologie
    Vandœuvre-lès-Nancy, 54511, France
  • Eugastro GmbH
    Leipzig, Saxony 4103, Germany
  • Medizinische Klinik für Gastroenterologie, Infektiologie, Rheumatologie charite
    Berlin, 12203, Germany
  • Krankenhaus Walfriede, Akademisches Lehrkrankenhaus der Charite
    Berlin, 14163, Germany
  • Agaplesion Markus Krankenhaus Medizinischen Klinik I, Gastroenterologie, Hepatologie, Onkologie, lnfektiologie
    Frankfurt, 60431, Germany
  • Universitatsklinikum Freiburg, Medizinische Klinik
    Freiburg, 79106, Germany
  • Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Zentrym für Innere Medizin
    Hannover, 30625, Germany
  • Klinik für Gastroenterologie, Pulmologie und allg. lnnere Medizin
    Köln, 5103, Germany
  • Universität Leipzig, Klinik f. Gastroenterologie und Rheumatologie
    Leipzig, 4103, Germany
  • Gastroenterologische Gemeinschaftspraxis Minden
    Minden, 32123, Germany
  • DRC Gyógyszervizsgáló Központ Kft.
    Balatonfüred, 8230, Hungary
  • Semmelweis University
    Budapest, 1088, Hungary
  • Semmelweis University, AOK Varosmajori Sziv- es Ergyogyaszati Klinika,
    Budapest, H-1031, Hungary
  • Bugat Pal Hospital
    Gyongyos, 3200, Hungary
  • Mater Misericordiae University Hospital
    Dublin, D07 RX49, Ireland
  • St. James's Hospital
    Dublin, Ireland
  • Gastroenterology Institute, Emek Medical Center
    Afula, 1834111, Israel
  • Barzilai Medical Center
    Ashkelon, 7830604, Israel
  • Clalit Health Services Jerusalem
    Jerusalem, 9362410, Israel
  • Institute of Gastroenterology, Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Humanitas Research Hospital, IBD Center
    Milan, 20089, Italy
  • A.0.U. di Modena - Policlinico S.C. di Gastroenterologia
    Modena, 41124, Italy
  • Fondazione IRCCS Policlinico San Matteo - Medicina Generale I
    Pavia, 27100, Italy
  • ASST Rhodense - Ospedale di Rho
    Rho, 20017, Italy
  • Fondazione Casa Sollievo della Sofferenza
    San Giovanni Rotondo, 71013, Italy
  • Centrum Opieki Zdrowotnej Orkan-med
    Ksawerów, 95-054, Poland
  • Medicome Sp. z o.o.
    Oświęcim, 32600, Poland
  • Centrum Medyczne Medyk
    Rzeszów, 35-526, Poland
  • Endoskopia sp. z o.o.
    Sopot, 81-756, Poland
  • WIP Warsaw IBD Point Profesor Kierkus
    Warszawa, 00-728, Poland
  • Oddział Kliniczny Gastroenterologii Ogólnej i Onkologicznej SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego UM
    Łódź, 90-153, Poland
  • MedLife Grivita
    Bucharest, 010719, Romania
  • Colentina Clinical Hospital
    Bucharest, 020125, Romania
  • University Hospital Bucharest
    Bucharest, 050098, Romania
  • Federal State Center of Coloproctology
    Moscow, 123423, Russian Federation
  • LLC Medical center Healthy family
    Novosibirsk, 630099, Russian Federation
  • Military Medical Academy
    Saint Petersburg, 191 124, Russian Federation
  • North-Western State Medical University n.a. I.I.Mechnikov
    Saint Petersburg, 191015, Russian Federation
  • Scientific Research Center Eco-Safety LLC
    Saint Petersburg, 196143, Russian Federation
  • Pavlov First Saint Petersburg State Medical University
    Saint Petersburg, 197022, Russian Federation
  • Saint-Petersburg State Medical Academy n.a. I.I. Mechnikov of Federal Agency of Healthcare & Social Development
    Saint-Petersburg, 195067, Russian Federation
  • Non state Public Health Institution "Railway clinical hospital on station Samara" of joint stock company Russian railways
    Samara, 403029, Russian Federation
  • Saratov State Medical University
    Saratov, 410054, Russian Federation
  • Siberia State Medical University
    Tomsk, 630055, Russian Federation
  • Clinical Center Zvezdara
    Belgrade, 11000, Serbia
  • Clinical-Hospital Centre Bezanijska Kosa - Gastroenterology Department
    Belgrade, 11080, Serbia
  • Clinical Hospital Center "Dr Dragisa Misovic-Dedinje"
    Belgrad, 11000, Serbia
  • Clinical Center Kragujevac
    Kragujevac, 34000, Serbia
  • Hospital Universitario Virgen de la Macarena
    Sevilla, 41009, Spain
  • Chernivtsi Regional Clinical Hospital
    Chernivtsi, 58001, Ukraine
  • Ivano-Frankivsk National Medical University, Regional Clinical Hospital
    Ivano-Frankivsk, 76008, Ukraine
  • Kharkiv City Clinical Hospital No 2 n.a. prof. O.O.Shalimov
    Kharkiv, 61037, Ukraine
  • Kiev City Clinical Hospital No. 1
    Kiev, 2091, Ukraine
  • Communal Institution of Kyiv Regional Council "Kyiv Regional Clinical Hospital"
    Kyiv, 04107, Ukraine
  • Ukrainian-German Gastroenterology Center "BYK-Kyiv"
    Kyiv, 1030, Ukraine
  • Volyn Regional Clinical Hospital
    Lutsk, 43000, Ukraine
  • Communal Nonprofit Enterprise "Lviv Clinical Emergency Care Hospital"
    Lviv, 79059, Ukraine
  • Communal Nonprofit Entreprise, "Lviv Clinical Emergency Care Hospital", 1st Therapeutic Dpt
    Lviv, 79059, Ukraine
  • Communal Nonprofit Enterprise "Odesa Regional Clinical Hospital"
    Odesa, 65025, Ukraine
  • Communal Nonprofit Enterprise "Ternopil University Hospital" of Ternopil Regional Council
    Ternopil, 46002, Ukraine
  • Municipal Institution "Uzhhorod Central District Hospital"
    Uzhhorod, 88009, Ukraine
  • Medical Center "Health Clinic"
    Vinnytsia, 21000, Ukraine
  • Communal Non-profit Enterprise "Vinnytsia City Clinical Hospital #1"
    Vinnytsia, 21029, Ukraine
  • Addenbrooke's Hospital
    Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • South Eastern Health & Social Care Trust, Ulster Hospital
    Belfast, Co Antrim BT161RH, United Kingdom
  • Royal Liverpool & Broadgreen University Hospitals NHS Trust
    Liverpool, Merseyside L7 8XP, United Kingdom
  • Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
    Birmingham, Warwickshire B15 2TH, United Kingdom
  • Barnsley Hospital NHS Foundation Trust
    Barnsley, Yorkshire S75 2EP, United Kingdom
  • University College London Hospital NHS Foundation Trust
    London, NWI 2BU, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, SE59RS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Apr 2021, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2019
First posted
Feb 19, 2019
StartActual
Jan 24, 2019
Primary completionActual
Apr 14, 2021
CompletionActual
Apr 14, 2021
Last update
May 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03844932
Lead sponsor
Sublimity Therapeutics Holdco Limited
Responsible party
Sponsor
First posted
Feb 19, 2019
Start date
Jan 24, 2019
Primary completion
Apr 14, 2021
Completion
Apr 14, 2021
Last update
May 7, 2021

Study contacts

Sponsor Responsible Medical Officer
study director · Sublimity Therapeutics (HoldCo) Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion